Literature DB >> 24570926

Statins: emerging role in chemoprevention for hepatocellular carcinoma?

Wai Meng Tai1, Han Chong Toh1.   

Abstract

Entities:  

Year:  2013        PMID： 24570926      PMCID： PMC3924662          DOI： 10.3978/j.issn.2304-3881.2012.10.05

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  19 in total

Review 1.  Pleiotropic effects of statins and their clinical significance.

Authors:  J C LaRosa
Journal:  Am J Cardiol       Date:  2001-08-01       Impact factor: 2.778

Review 2.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.

Authors:  P R Hebert; J M Gaziano; K S Chan; C H Hennekens
Journal:  JAMA       Date:  1997 Jul 23-30       Impact factor: 56.272

3.  Statin use and the risk of liver cancer: a population-based case–control study.

Authors:  Hui-Fen Chiu; Shu-Chen Ho; Chih-Cheng Chen; Chun-Yuh Yang
Journal:  Am J Gastroenterol       Date:  2010-12-14       Impact factor: 10.864

4.  Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.

Authors:  Yu-Tse Tsan; Chang-Hsing Lee; Jung-Der Wang; Pau-Chung Chen
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

5.  Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort.

Authors:  Eric J Jacobs; Carmen Rodriguez; Kerri A Brady; Cari J Connell; Michael J Thun; Eugenia E Calle
Journal:  J Natl Cancer Inst       Date:  2006-01-04       Impact factor: 13.506

6.  Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials.

Authors:  Stefanos Bonovas; Kalitsa Filioussi; Nikolaos Tsavaris; Nikolaos M Sitaras
Journal:  J Clin Oncol       Date:  2006-09-25       Impact factor: 44.544

7.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

Authors:  L Blais; A Desgagné; J LeLorier
Journal:  Arch Intern Med       Date:  2000 Aug 14-28

8.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.